130 related articles for article (PubMed ID: 2004327)
1. Bladder cancer. Human leukocyte antigen II, interleukin-6, and interleukin-6 receptor expression determined by the polymerase chain reaction.
Meyers FJ; Gumerlock PH; Kawasaki ES; Wang AM; deVere White RW; Erlich HA
Cancer; 1991 Apr; 67(8):2087-95. PubMed ID: 2004327
[TBL] [Abstract][Full Text] [Related]
2. Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue.
Shen SS; Smith CL; Hsieh JT; Yu J; Kim IY; Jian W; Sonpavde G; Ayala GE; Younes M; Lerner SP
Cancer; 2006 Jun; 106(12):2610-6. PubMed ID: 16700038
[TBL] [Abstract][Full Text] [Related]
3. Molecular characterization of major histocompatibility complex class II gene expression and demonstration of antigen-specific T cell response indicate a new phenotype in class II-deficient patients.
Hauber I; Gulle H; Wolf HM; Maris M; Eggenbauer H; Eibl MM
J Exp Med; 1995 Apr; 181(4):1411-23. PubMed ID: 7699327
[TBL] [Abstract][Full Text] [Related]
4. Quantitative detection of cytokeratin 20 mRNA expression in bladder carcinoma by real-time reverse transcriptase-polymerase chain reaction.
Christoph F; Müller M; Schostak M; Soong R; Tabiti K; Miller K
Urology; 2004 Jul; 64(1):157-61. PubMed ID: 15245962
[TBL] [Abstract][Full Text] [Related]
5. Molecular alterations of E-cadherin gene: possible role in human bladder carcinogenesis.
Taddei I; Piazzini M; Bartoletti R; Dal Canto M; Sardi I
Int J Mol Med; 2000 Aug; 6(2):201-8. PubMed ID: 10891567
[TBL] [Abstract][Full Text] [Related]
6. Increased mdr1 gene transcript levels in high-grade carcinoma of the bladder determined by quantitative PCR-based assay.
Clifford SC; Thomas DJ; Neal DE; Lunec J
Br J Cancer; 1994 Apr; 69(4):680-6. PubMed ID: 7908215
[TBL] [Abstract][Full Text] [Related]
7. Expression of transforming growth factor-beta 1 in human bladder cancer.
Miyamoto H; Kubota Y; Shuin T; Torigoe S; Dobashi Y; Hosaka M
Cancer; 1995 May; 75(10):2565-70. PubMed ID: 7736402
[TBL] [Abstract][Full Text] [Related]
8. Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status.
Maas S; Warskulat U; Steinhoff C; Mueller W; Grimm MO; Schulz WA; Seifert HH
Urology; 2004 Feb; 63(2):392-7. PubMed ID: 14972509
[TBL] [Abstract][Full Text] [Related]
9. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder.
Raman JD; Mongan NP; Tickoo SK; Boorjian SA; Scherr DS; Gudas LJ
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8570-6. PubMed ID: 16361539
[TBL] [Abstract][Full Text] [Related]
10. Frequent association of p53 gene mutation in invasive bladder cancer.
Fujimoto K; Yamada Y; Okajima E; Kakizoe T; Sasaki H; Sugimura T; Terada M
Cancer Res; 1992 Mar; 52(6):1393-8. PubMed ID: 1540947
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder.
Izawa JI; Slaton JW; Kedar D; Karashima T; Perrotte P; Czerniak B; Grossman HB; Dinney CP
Oncol Rep; 2001; 8(1):9-15. PubMed ID: 11115562
[TBL] [Abstract][Full Text] [Related]
12. Comparison of multidrug resistance gene expression levels with malignant potentials and influence of chemotherapy in urothelial cancers.
Kakehi Y; Wu WJ; Kim WJ; Arao S; Fukumoto M; Yoshida O
Int J Urol; 1995 Nov; 2(5):309-15. PubMed ID: 8749949
[TBL] [Abstract][Full Text] [Related]
13. High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the bladder.
Gonzalez-Zulueta M; Shibata A; Ohneseit PF; Spruck CH; Busch C; Shamaa M; El-Baz M; Nichols PW; Gonzalgo ML; Elbaz M [corrected to El-Baz M]
J Natl Cancer Inst; 1995 Sep; 87(18):1383-93. PubMed ID: 7658499
[TBL] [Abstract][Full Text] [Related]
14. Association of nucleophosmin/B23 mRNA expression with clinical outcome in patients with bladder carcinoma.
Tsui KH; Cheng AJ; Chang Pe; Pan TL; Yung BY
Urology; 2004 Oct; 64(4):839-44. PubMed ID: 15491744
[TBL] [Abstract][Full Text] [Related]
15. Differentially expressed genes in metastatic advanced Egyptian bladder cancer.
Zekri AR; Hassan ZK; Bahnassy AA; Khaled HM; El-Rouby MN; Haggag RM; Abu-Taleb FM
Asian Pac J Cancer Prev; 2015; 16(8):3543-9. PubMed ID: 25921176
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of deleted in malignant brain tumors 1 (DMBT1) gene expression in bladder carcinoma cases: preliminary study.
Dodurga Y; Avci CB; Yilmaz S; Dogan ZO; Kesen Z; Tataroglu C; Satiroglu-Tufan NL; Bushra T; Gunduz C
Biomarkers; 2011 Nov; 16(7):610-5. PubMed ID: 21999583
[TBL] [Abstract][Full Text] [Related]
17. Development of a multiplex RNA urine test for the detection and stratification of transitional cell carcinoma of the bladder.
Holyoake A; O'Sullivan P; Pollock R; Best T; Watanabe J; Kajita Y; Matsui Y; Ito M; Nishiyama H; Kerr N; da Silva Tatley F; Cambridge L; Toro T; Ogawa O; Guilford P
Clin Cancer Res; 2008 Feb; 14(3):742-9. PubMed ID: 18245534
[TBL] [Abstract][Full Text] [Related]
18. Expression analysis of VEGF-A and VEGF-B: relationship with clinicopathological parameters in bladder cancer.
Fauconnet S; Bernardini S; Lascombe I; Boiteux G; Clairotte A; Monnien F; Chabannes E; Bittard H
Oncol Rep; 2009 Jun; 21(6):1495-504. PubMed ID: 19424629
[TBL] [Abstract][Full Text] [Related]
19. Progressive loss of CD44 gene expression in invasive bladder cancer.
Sugino T; Gorham H; Yoshida K; Bolodeoku J; Nargund V; Cranston D; Goodison S; Tarin D
Am J Pathol; 1996 Sep; 149(3):873-82. PubMed ID: 8780391
[TBL] [Abstract][Full Text] [Related]
20. Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles.
Modlich O; Prisack HB; Pitschke G; Ramp U; Ackermann R; Bojar H; Vögeli TA; Grimm MO
Clin Cancer Res; 2004 May; 10(10):3410-21. PubMed ID: 15161696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
